245 related articles for article (PubMed ID: 6502914)
21. Effect of spironolactone on cytosolic free sodium concentration in platelets from hypertensive patients with primary aldosteronism.
Tepel M; Husseini S; Zidek W
Eur J Clin Pharmacol; 1993; 44 Suppl 1():S51-2. PubMed ID: 8387426
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic value of calcium antagonists in autonomous hyperaldosteronism.
Stimpel M; Ivens K; Volkmann HP; Wambach G; Kaufmann W
Klin Wochenschr; 1989 Feb; 67(4):248-52. PubMed ID: 2648061
[TBL] [Abstract][Full Text] [Related]
23. [The effect of trilostane, a new inhibitor of adrenal steroid biosynthesis, on blood pressure, plasma aldosterone and other steroid hormones, serum potassium and plasma renin activity in primary aldosteronism (author's transl)].
Shigetomi S; Fukuchi S; Haruyama K; Yamazaki M
Nihon Naibunpi Gakkai Zasshi; 1982 Mar; 58(3):184-98. PubMed ID: 6212269
[TBL] [Abstract][Full Text] [Related]
24. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention.
Hensen J; Abraham WT; Dürr JA; Schrier RW
Am J Nephrol; 1991; 11(6):441-6. PubMed ID: 1840232
[TBL] [Abstract][Full Text] [Related]
25. Role of aldosterone in the antihypertensive effect of spironolactone in essential hypertension.
Benraad H; Drayer J; Hoefnagels W; Kloppenborg P; Benraad T
Clin Pharmacol Ther; 1978 Dec; 24(6):638-43. PubMed ID: 710023
[TBL] [Abstract][Full Text] [Related]
26. Spironolactone and triamterene in volume-dependent essential hypertension.
DeCarvalho JG; Emery AC; Frohlich ED
Clin Pharmacol Ther; 1980 Jan; 27(1):53-6. PubMed ID: 6985854
[TBL] [Abstract][Full Text] [Related]
27. [Aldosterone-to-renin ratio threshold for screening primary aldosteronism in Chinese hypertensive patients].
Chen SX; Du YL; Zhang J; Gong YC; Hu YR; Chu SL; He QB; Song YY; Zhu DL
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):868-72. PubMed ID: 17217708
[TBL] [Abstract][Full Text] [Related]
28. Effect of spironolactone on urinary kallikrein excretion in patients with essential hypertension and in primary aldosteronism.
Seino M; Abe K; Sakurai Y; Irokawa N; Yasujima M; Chiba S; Otsuka Y; Yoshinaga K
Tohoku J Exp Med; 1977 Feb; 121(2):111-9. PubMed ID: 847738
[TBL] [Abstract][Full Text] [Related]
29. An abnormal sodium metabolism in Japanese patients with essential hypertension, judged by serum sodium distribution, renal function and the renin-aldosterone system.
Komiya I; Yamada T; Takasu N; Asawa T; Akamine H; Yagi N; Nagasawa Y; Ohtsuka H; Miyahara Y; Sakai H; Sato A; Aizawa T
J Hypertens; 1997 Jan; 15(1):65-72. PubMed ID: 9050972
[TBL] [Abstract][Full Text] [Related]
30. Non-modulating hypertension: evidence for the involvement of kallikrein/kinin activity associated with overactivity of the renin-angiotensin system. Successful blood pressure control during long-term Na+ restriction.
Sanchez R; Gimenez MI; Ramos F; Baglivo H; Ramirez AJ
J Hypertens; 1996 Nov; 14(11):1287-91. PubMed ID: 8934356
[TBL] [Abstract][Full Text] [Related]
31. Insulin sensitivity in patients with primary aldosteronism: a follow-up study.
Catena C; Lapenna R; Baroselli S; Nadalini E; Colussi G; Novello M; Favret G; Melis A; Cavarape A; Sechi LA
J Clin Endocrinol Metab; 2006 Sep; 91(9):3457-63. PubMed ID: 16822818
[TBL] [Abstract][Full Text] [Related]
32. Activation of aldosterone secretion in primary aldosteronism.
Spark RF; Dale SL; Kahn PC; Melby JC
J Clin Invest; 1969 Jan; 48(1):96-104. PubMed ID: 4303791
[TBL] [Abstract][Full Text] [Related]
33. Albuminuria in untreated patients with primary aldosteronism or essential hypertension.
Halimi JM; Mimran A
J Hypertens; 1995 Dec; 13(12 Pt 2):1801-2. PubMed ID: 8903655
[TBL] [Abstract][Full Text] [Related]
34. Primary aldosteronism: effects of inhibition of ACTH and potassium administration on plasma aldosterone concentration.
Ganguly A; Luetscher JA; Weinberger MH
Clin Exp Hypertens A; 1982; 4(9-10):1695-714. PubMed ID: 6291813
[TBL] [Abstract][Full Text] [Related]
35. Aldosterone response to adrenocorticotrophin and furosemide in primary aldosteronism after prolonged spironolactone treatment.
Yagi A; Ichikawa S; Sakamaki T; Ono Z; Sato K; Nakamura T; Sakamoto H; Murata K
Eur J Endocrinol; 1994 Sep; 131(3):215-20. PubMed ID: 7921203
[TBL] [Abstract][Full Text] [Related]
36. Similarity of idiopathic aldosteronism and essential hypertension. A statistical comparison.
McAreavey D; Murray GD; Lever AF; Robertson JI
Hypertension; 1983; 5(1):116-21. PubMed ID: 6336718
[TBL] [Abstract][Full Text] [Related]
37. [Relation between dopamine secretion and saltsensitivity in essential hypertension].
Haruyama K; Shigetomi S; Yamazaki M; Hashimoto S; Yaginuma K; Fukuchi S
Nihon Naibunpi Gakkai Zasshi; 1983 Oct; 59(10):1658-66. PubMed ID: 6363145
[TBL] [Abstract][Full Text] [Related]
38. Primary aldosteronism -- screening, diagnosis and therapy.
Horký K; Gregorová I; Vancura J; Silinková-Málková E; Hradec E
Cor Vasa; 1981; 23(4):265-79. PubMed ID: 7028394
[TBL] [Abstract][Full Text] [Related]
39. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism.
Karashima S; Yoneda T; Kometani M; Ohe M; Mori S; Sawamura T; Furukawa K; Seta T; Yamagishi M; Takeda Y
Hypertens Res; 2016 Mar; 39(3):133-7. PubMed ID: 26606875
[TBL] [Abstract][Full Text] [Related]
40. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
Hood SJ; Taylor KP; Ashby MJ; Brown MJ
Circulation; 2007 Jul; 116(3):268-75. PubMed ID: 17606839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
